Monroe Capital was the sole lead arranger and administrative agent on the funding of a $20 million senior credit facility to Cytovance Biologics, a portfolio company of Great Point Partners since March 2011.
Cytovance is a contract manufacturing organization of mammalian and microbial biologics. The company works with biotechnology and pharmaceutical companies in the development and manufacturing of proteins, antibodies, and cell-based therapeutic products. Cytovance is based in Oklahoma City, OK (www.cytovance.com).
Monroe Capital provides senior and junior debt and equity co-investments to middle-market companies. This transaction with Great Point Partners and Cytovance is representative of Monroe Capital’s capabilities in its healthcare vertical. Prior to the Cytovance transaction, Monroe Capital provided a $14 million senior secured credit facility to support the recapitalization of Starpoint Health, an ambulatory surgery center operator and a portfolio company of Caltius Equity Partners. This transaction closed in July 2014.
Monroe Capital was founded in 2004 and maintains offices in Chicago, Atlanta, Boston, Charlotte, Dallas, Los Angeles, New York and San Francisco (www.monroecap.com).
2014 PEPD • Private Equity’s Leading News Magazine • 10-28-14
